TUNICRIS-julkaisut - Trepo

Viitteet 1-2 / 2

Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial

Pal, Sumanta K.; Puente, Javier; Heng, Daniel Y.C.; Glen, Hilary; Koralewski, Piotr; Stroyakovskiy, Daniil; Alekseev, Boris; Parnis, Francis; Castellano, Daniel; Ciuleanu, Tudor; Lee, Jae Lyun; Sunela, Kaisa; O'Hara, Karen; Binder, Terri A.; Peng, Lixian; Smith, Alan D.; Rha, Sun Young (2022)
article

<p>Background: Lenvatinib (18 mg) plus everolimus (5 mg) is approved for patients with advanced renal cell carcinoma (RCC) after one or more prior antiangiogenic therapies. Objective: To assess whether a lower starting ...
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma

Bergerot, Cristiane; Rha, Sun Young; Pal, Sumanta; Koralewski, Piotr; Stroyakovskiy, Daniil; Alekseev, Boris; Parnis, Francis; Castellano, Daniel; Lee, Jae-Lyun; Sunela, Kaisa; Ciuleanu, Tudor; Heng, Daniel; Glen, Hilary; Wang, J.; Bennett, Lee; Pan, Janice; O'Hara, Karen; Puente, J. (01 / 2023)
article

Background: Preserving health-related quality of life (HRQOL) is an important goal during renal cell carcinoma treatment. We report HRQOL outcomes from a phase II trial (NCT03173560).<br/><br/>Patients and ...